Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: Role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration

Molecular Pharmacology

Volumn 55, Issue 4, 1999, Pages 761-769

  Jansen, Gerrit ^a   Barr, Haim ^c   Kathmann, Ietje ^a   Bunni, Marlene A ^b   Priest, David G ^b   Noordhuis, Paul ^a   Peters, Godefridus J ^a   Assaraf, Yehuda G ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; LOMETREXOL; METHOTREXATE; PYRIMETHAMINE; TRIMETREXATE;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CHO CELL; DRUG DISTRIBUTION; DRUG MECHANISM; ENZYME ACTIVITY; INFECTION; LYSOSOME; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CELLS, CULTURED; CHO CELLS; CRICETINAE; DRUG RESISTANCE; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUCOSE; LYSOSOMES; METHOTREXATE; PEPTIDE SYNTHASES; PROTEINS; PTEROYLPOLYGLUTAMIC ACIDS; PYRIMETHAMINE; TRITIUM;

EID: 0032916531     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Antony AC (1992) The biological chemistry of folate receptors. Blood 79:2807-2820.
2. Assaraf YG, Babani S and Goldman ID (1998) Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. J Biol Chem 273:8106-8111.
3. Assaraf YG and Goldman ID (1997) Loss of folic acid exporter function with a markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem 272:17460-17466.
4. Assaraf YG, Molina A and Schimke RT (1989a) Sequential amplification of dihydrofolate reductase and multidrug resistance genes in Chinese hamster ovary cells selected for stepwise resistance to the lipid-soluble antifolate trimetrexate. J Biol Chem 264:18326-18334.
5. Assaraf YG, Molina A and Schimke RT (1989b) Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype. J Natl Cancer Inst 81:290-294.
6. Assaraf YG and Slotky JI (1993) Characterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine. J Biol Chem 268:4556-4566.
7. Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA and Masur H (1987) Potent in vitro and in vivo antitoxoplasma activity of the lipid soluble antifolate trimetrexate. J Clin Invest 79:478-482.
8. Beardsley GP, Moroson BA, Taylor EC and Moran RG (1989) A new folate antimetabolite 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of the de novo purine synthesis. J Biol Chem 264:328-333.
9. Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11:5-14.
10. Boritzki TJ, Bartlett CA, Zhang C, Howland EF, Margosiak SA, Palmer CL, Romines WH and Jackson RC (1996) AG2034: A novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 14:295-303.
11. Borst P and Ouelette M (1995) New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 49:427-460.
12. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
13. Bunni M, Sirotnak FM, Otter GM and Priest DG (1994) Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice. Cancer Chemother Pharmacol 34:455-458.
14. Cavallito JC, Nichol CA, Brenckman WD, Deangelis RL, Stickney DR, Simmons WS and Sigel CW (1978) Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog and man. Drug Metab and Dispos 6:329-337.
15. Chen L, Qi H, Korenberg J, Garrow TA, Choi YJ and Shane BA (1996) Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization, and differential splicing of its gene. J Biol Chem 271:13077-13087.
16. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Health LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K and Wilson HR (1993) The biochemical and cellular pharmacology of 1843U89, a novel benzoquinoline inhibitor of thymidylate synthase. Cancer Res 53:810-818.
17. Goldman ID and Matherly LH (1985) The cellular pharmacology of methotrexate. Pharmacol Ther 28:77-102.
18. Hall CW, Liebaers I, DiNatale P and Neufeld EF (1978) Enzymatic diagnosis of the mucopolysaccharide storage disorders. Methods Enzymol 50:439-456.
19. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith M, Wardleworth M, Ward W and Boyle FT (1997) The cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331, a water soluble, nonpolyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911-921.
20. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR (1991) ICI-D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical studies. Cancer Res 51:5579-5586.
21. Jansen G (1998a) Receptor-and carrier-mediated transport systems for folates and antifolates: Exploitation for folate-based chemotherapy and immunotherapy, in Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy (Jackman AL ed) pp 293-321, Humana Press, Totowa.
22. Jansen G, Mauritz R, Assaraf YG, Sprecher H, Drori S, Kathmann I, Westerhof GR, Priest DG, Bunni MA, Pinedo HM, Schornagel JH and Peters GJ (1997) Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and -resistant leukemia cells. Adv Enzyme Regul 37:59-76.
23. Jansen G, Mauritz R, Drori S, Sprecher H, Kathmann I, Bunni M, Priest DG, Noordhuis P, Schornagel JH, Pinedo HM, Peters GJ and Assaraf YG (1998b) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273:30189-30198.
24. Jansen G, Schornagel JH, Kathmann I, Westerhof GR, Hordijk GJ and Van der Laan BFAM (1992) Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res 4:299-305.
25. Jones TR, Welsh KM, Webber S, Davies J, Janson CA, Matthews DA, Smith WW, Johnston AL, Shetty BV, Lewis KK, Cadwell AM, Romines WH, Herrmann SM, Galivan J, O'Connor BM, Rhee MS and Von Hoff DD (1992) New lipophilic antifolates acting upon dihydrofolate reductase. Proc Am Assoc Cancer Res 33:412.
26. McGuire JJ, Hseih P, Coward JK and Bertino JE (1980) Enzymatic synthesis of folylpolyglutamates. J Biol Chem 225:5776-5788.
27. O'Connor BM, Rotundo RF, Nimec Z, McGuire JJ and Galivan J (1991) Secretion of γ-glutamyl hydrolase in vitro. Cancer Res 51:3874-3881.
28. Osborne CB, Lowe KE and Shane B (1993) Regulation of folate and one-carbon metabolism in mammalian cells. 1. Folate metabolism in Chinese hamster ovary cells expressing Escherichia coli or human folylpoly-γ-glutamate synthetase activity. J Biol Chem 268:21657-21664.
29. Rhee MS, Galivan J, Wright JE and Rosowsky A (1994) Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. Mol Pharmacol 45:783-791.
30. Roberts WL, Reynolds KM, Heimer R, Jatlow PI and Rainey PM (1995) Pyrimethamine analysis by enzyme inhibition and HPLC analysis. Am J Clin Pathol 104:82-88.
31. Sierra EE and Goldman ID (1998) Characterization of folate transport mediated by a low pH route in mouse L1210 leukemia cells with defective reduced folate carrier function. Biochem Pharmacol 55:1505-1512.
32. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Schackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57:1116-1123.
33. Sirotnak FM (1985) Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: Biological significance and implications for improved therapy of human cancer. Cancer Res 45:3992-4000.
34. Sirotnak FM, Schmid FA, Samuels LL and DeGraw JI (1987) 10-Ethyl-10-deazaaminopterin: Structural design and biochemical pharmacology and antitumor properties. NCI Monographs 5:127-131
35. Sprecher H, Barr HM, Slotky JI, Tzukerman M, Eytan GD and Assaraf YG (1995) Alteration of mitochondrial gene expression and disruption of respiratory function by the lipophilic antifolate pyrimethamine in mammalian cells. J Biol Chem 270:20668-20676.
36. Traganos F and Darzynkiewicz Z (1994) Lysosomal proton pump activity: Supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol 41:185-194.
37. Warren L, Jardillier JC and Ordentlich P (1991) Secretion of lysosomal enzymes by drug sensitive and multiple drug-resistant cells. Cancer Res 51:1996-2001.
38. Webber S, Bartlett CA, Boritzki TJ, Hillard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA and Shetty BV (1996) AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 37:509-517.
39. Westerhof GR, Rijnboutt S, Schornagel JH, Pinedo HM, Peters GJ and Jansen G (1995a) Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate binding protein. Cancer Res 55:3795-3802.
40. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM and Jansen G (1995b) Carrier-and receptor-mediated transport of folate antagonists targeting folate dependent enzymes: Correlates of molecular structure and biological activity. Mol Pharmacol 48:459-471.